138 related articles for article (PubMed ID: 4801258)
1. [Dopaminergic control of the diencephalo-pituitary axis for somatotropin secretion].
Cavagnini F; Pontiroli AE; Raggi U; Peracchi M; Malinverni A
Folia Endocrinol; 1973 Dec; 26(6):483-9. PubMed ID: 4801258
[No Abstract] [Full Text] [Related]
2. [Influence of thyroid hormones on the diencephalo-pituitary axis for somatotropin secretion].
Cavagnini F; Raggi U; Peracchi M; Pontiroli AE; Malinverni A
Folia Endocrinol; 1973 Dec; 26(6):490-6. PubMed ID: 4801259
[No Abstract] [Full Text] [Related]
3. [L-DOPA-and dopa-decarboxylase inhibitor combination for the treatment of Parkinsonism].
Fujimori N; Kito S; Yamamoto M; Itoga E; Kosaka K
Nihon Rinsho; 1974 Mar; 32(3):579-86. PubMed ID: 4859014
[No Abstract] [Full Text] [Related]
4. Release of human growth hormone, follicle stimulating hormone, and luteinizing hormone in response to L-dihydroxy-phenylalanine (L-dopa) in normal man.
Perlow MJ; Sassin JF; Boyar R; Hellman L; Weitzman ED
Dis Nerv Syst; 1972 Dec; 33(12):804-10. PubMed ID: 4668972
[No Abstract] [Full Text] [Related]
5. [L-dopa and somatotropin secretion in humans].
Giordano G; Marugo M; Minuto F; Barreca T; Foppiani E
Folia Endocrinol; 1973 Dec; 26(6):523-37. PubMed ID: 4801262
[No Abstract] [Full Text] [Related]
6. [Drug therapy of Parkinson's syndrome. Clinical long-term study using L-dopa and the drug conbination L-dopa-decarboxylase inhibitor].
Christiani K; Möller WD
Munch Med Wochenschr; 1973 Apr; 115(16):711-3. PubMed ID: 4197759
[No Abstract] [Full Text] [Related]
7. [Quantitative rigor determination in Parkinson's disease. Myo-integration for therapy control of L-Dopa in combination with a decarboxylase inhibitor (Ro 8-0576)].
Gehlen W; Eisenlohr JJ
Nervenarzt; 1974 Jan; 45(2):22-9. PubMed ID: 4601993
[No Abstract] [Full Text] [Related]
8. [Treatment of Parkinson's syndrome with L-dopa and a decarboxylase inhibitor].
Lombardo L; de la Garza R; Ivan-Reynoso G
Arch Invest Med (Mex); 1974; 5(2):105-16. PubMed ID: 4433198
[No Abstract] [Full Text] [Related]
9. Stimulation of human-growth-hormone secretion by L-dopa.
Boyd AE; Lebovitz HE; Pfeiffer JB
N Engl J Med; 1970 Dec; 283(26):1425-9. PubMed ID: 5481776
[No Abstract] [Full Text] [Related]
10. [Therapy of Parkinsonism using L-dopa in combination with a decarboxylase inhibitor].
Stammler A; Vielhaber K
Fortschr Neurol Psychiatr Grenzgeb; 1972 Oct; 40(10):564-8. PubMed ID: 4565521
[No Abstract] [Full Text] [Related]
11. [Growth hormone secretion induced by L-Dopa and a dopa decarboxylase inhibitor blocked by free fatty acids].
Casanueva F; Villanueva L; Peñalva A; Barrionuevo JA; Vila T; Cabezas-Cerrato J
Rev Clin Esp; 1979 May; 153(3):221-4. PubMed ID: 482695
[No Abstract] [Full Text] [Related]
12. [Advances in L-DOPA therapy for parkinsonism through combination with a decarboxylase inhibitor. Results of a long-term study].
Wälzholz U; Schönfelder H
Nervenarzt; 1972 Oct; 43(10):531-2. PubMed ID: 4628192
[No Abstract] [Full Text] [Related]
13. Amantadine enhancement of L-DOPA induced growth hormone stimulation.
Massara F; Camanni F; Molinatti GM
Horm Metab Res; 1973 Nov; 5(6):454-6. PubMed ID: 4767002
[No Abstract] [Full Text] [Related]
14. [Therapeutic association of L-dopa and an inhibitor of peripheral decarboxylase in Parkinsonism. Preliminary results].
De Divitiis E; Cerillo A; Tata MR; Decina A
Acta Neurol (Napoli); 1973; 28(2):208-12. PubMed ID: 4709076
[No Abstract] [Full Text] [Related]
15. L-Dopa, B 6 , and alpha-methyldopa hydrazine.
Klawans HL; Ringel SP
Confin Neurol; 1973; 35(3):186-92. PubMed ID: 4712885
[No Abstract] [Full Text] [Related]
16. [Action of a peripheral inhibitor of dopa-decarboxylase on the inhibition by L-DOPA of the hypothalamo-hypophyseo-adrenocortical system in man].
Balestreri R; Bertolini S; Elicio N; Costa S
Boll Soc Ital Biol Sper; 1974 Jul; 50(12):832-7. PubMed ID: 4447697
[No Abstract] [Full Text] [Related]
17. [Effect of the combined treatment of Parkinson patients with L-Dopa and a decarboxylase inhibitor (Ro4-4602). Quantitative analysis of bradykinesia by means of reaction time measurements].
Kaufmann W; Butz P; Wiesendanger M
Dtsch Z Nervenheilkd; 1970; 197(1):85-100. PubMed ID: 5522871
[No Abstract] [Full Text] [Related]
18. [Attempt at potentiation of the action of L-dopa on the secretion of growth hormone by benserazide, disulfiram and propranolol].
Rochiccioli P; Enjaume P; Dutau G; Ribot C; Augier D
Arch Fr Pediatr; 1976 Jan; 33(1):55-66. PubMed ID: 985031
[TBL] [Abstract][Full Text] [Related]
19. The role of brain 5-hydroxytryptamine in the central action of L-DOPA.
Maj J; Pawlowski L; Sarnek J
Adv Biochem Psychopharmacol; 1974; 10():253-6. PubMed ID: 4846541
[No Abstract] [Full Text] [Related]
20. [Pharmacokinetic and pharmacodynamic aspects of L-DOPA treatment and dopadecarboxilase inhibitors and dopaminergic antagonists in Parkinson's disease (author's transl)].
García de Yébenes J; Avila C; Bazán E; García E; Gervás J; Maseda C; Mena M; Muradas V; Ramos JA
Med Clin (Barc); 1982 Apr; 78(7):259-64. PubMed ID: 7087591
[No Abstract] [Full Text] [Related]
[Next] [New Search]
